Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on reaching clinical milestones. The news sent Swedish firm CombiGene’s…
Positive safety data for long-term use of MS drug Kesimpta
Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods. Novartis announced the findings at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), revealing that…
Digital therapeutics world first for Big Health in Scotland
UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety and insomnia digital therapeutics available on a national basis. NHS Scotland will offer the digital health firm’s Sleepio and Daylight, and the…
Headspace and Ginger finalise $3bn digital mental health merger
Headspace and Ginger have completed their $3 billion combination to create Headspace Health, a new frontrunner in the rapidly growing digital mental health and wellbeing sectors. The company will be led by Ginger’s former CEO Russell Glass, while Headspace’s co-founders…
New name, powers at par with US FDA: Govt kickstarts makeover of CDSCO
As part of the makeover, the government will take steps to establish a training academy, new drug testing laboratories and upgrade the existing central laboratories. The Narendra Modi government has kick-started the process to revamp the country’s apex drug and…
Gene Therapy in One Eye Improves Vision in Both Eyes
It’s not clear why the patients with Leber hereditary optic neuropathy, a mitochondrial disorder that causes blindness, also experienced the modest benefits in their untreated eye. I n a Phase 3 gene therapy trial intended to improve vision among patients…
Kintor doses first patient in Phase III clinical trial of Covid-19 therapy
The trial is approved by the US FDA and ANVISA and is seeking approval from regulatory agencies in Europe and Asia. Kintor Pharmaceutical has dosed the first subject in the US for the Phase III clinical trial of its oral…
Pacific Cancer Care to use Deep Lens’ AI solutions for clinical trials
Pacific Cancer Care will use Deep Lens’ artificial intelligence (AI)-based solutions to streamline its clinical trial matching and expedite enrolment for cancer patients after the companies entered a partnership. The collaboration will extend Pacific Cancer Care’s current clinical trial offering…
Arcturus obtains approval for Phase IIIb Covid vaccine trial in Vietnam
The trial will have nearly 20,000 subjects, who will receive two doses of the vaccine 28 days apart or a placebo. The Vietnam Ministry of Health has granted approval to Arcturus Therapeutics for commencing the Phase IIIb portion of Phase…
